Donor‐Related Factors Affecting Haploidentical HSCT Outcomes in Acute Leukemia: A Single‐Center Retrospective Cohort Study of a Modified Combination of Anti‐Thymocyte Globulin and Post‐Transplant Cyclophosphamide
Retrospective cohort study assesses donor characteristics influencing outcomes in acute leukemia, suggesting implications for donor selection.
Key Points
This study aimed to evaluate how donor characteristics affect outcomes of haploidentical HSCT in acute leukemia.
Retrospective cohort study analyzing 159 adults with acute myeloid or lymphoblastic leukemia who received haplo‐HSCT.
Outcomes analyzed included overall survival, disease-free survival, and graft-versus-host disease-free survival using Kaplan–Meier and Fine–Gray methods.
Predictors were evaluated using multivariable Cox regression.
At 36 months, overall survival was 52.7% for AML patients with sibling donors.
Offspring donors showed numerically lower survival in ALL patients and higher relapse rates.
Older recipient age (HR, 1.03 per year; 95% CI, 1.01–1.05; p < 0.001) was correlated with worse overall survival.